LABT · NASDAQ

Lakewood-Amedex Biotherapeutics Inc.

Q: How do I get LABT news from the API?

Call GET /v1/news?tickers=LABT. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.

$0.26 +0.06 (+30.00%)

Company overview

This biopharmaceutical company is dedicated to developing innovative antimicrobial therapies. Its array of anti-infective products is designed to tackle specific viral conditions, including avian influenza, Epstein-Barr Virus (EBV), and hepatitis B and C. Established by Roderic Dale on July 11, 2006, the firm maintains its principal office in Bradenton, Florida.

Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ
Market cap: $455,171
Employees: 5
Headquarters: University Park, FL
Website: lakewoodamedex.com
CEO: Kelvin Cooper
Listed: April 23, 2026
P/E: 0.00
Dividend yield: 0.00%

Company financials

Total assets: $196,343
Total debt: $1.8M

Price chart

LABT 1D NASDAQ O0.19H0.20L0.17C0.20+0.00 (+2.51%)Vol670.20K

News

Ticker	Type	Headline	Source	Published
LABTLakewood-Amedex Biotherapeutics Inc.	Press release	Lakewood-Amedex Biotherapeutics Announces Completion of Series C Convertible Preferred Stock Redemption	PR Newswire	Nov 5, 8:02:03 AM ET
LABTLakewood-Amedex Biotherapeutics Inc.	Press release	Lakewood-Amedex Biotherapeutics Presents Data Highlighting Nu-3's Broad-Spectrum Antimicrobial Activity and Low Potential for Resistance at IDWeek 2026 Lakewood-Amedex Biotherapeutics Inc., (NASDAQ: LABT, the "Company"), a clinical-stage bi.	PR Newswire	Oct 21, 8:02:00 AM ET
LABTLakewood-Amedex Biotherapeutics Inc.	Stock news	Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Stock Short Interest Jumps 146.8%	Defense World	Oct 13, 3:21:27 AM ET
LABTLakewood-Amedex Biotherapeutics Inc.	Press release	Lakewood-Amedex Biotherapeutics Announces Positive Preclinical Data in Urinary Tract and Pulmonary Infection Indications with Bisphosphocin® Compounds	PRNewsWire	Oct 7, 8:02:00 AM ET
LABTLakewood-Amedex Biotherapeutics Inc.	Press release	Lakewood-Amedex Biotherapeutics Announces Participation in October Conferences	PR Newswire	Oct 1, 8:02:00 AM ET
LABTLakewood-Amedex Biotherapeutics Inc.	Press release	Lakewood-Amedex Biotherapeutics Announces Positive Data Against Recent Clinical Isolates from Infected Diabetic Foot Ulcers	PR Newswire	Sep 28, 8:02:00 AM ET
LABTLakewood-Amedex Biotherapeutics Inc.	Press release	Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers	PR Newswire	Sep 24, 8:02:00 AM ET
LABTLakewood-Amedex Biotherapeutics Inc.	Press release	Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3	PR Newswire	Sep 21, 8:02:00 AM ET
LABTLakewood-Amedex Biotherapeutics Inc.	Stock news	Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers	PRNewsWire	Sep 18, 8:13:00 AM ET
LABTLakewood-Amedex Biotherapeutics Inc.	Press release	Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference	PRNewsWire	Sep 8, 8:02:00 AM ET
LABTLakewood-Amedex Biotherapeutics Inc.	Stock news	Why Pyxis Tankers Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket	Benzinga	Sep 1, 4:35:40 AM ET
LABTLakewood-Amedex Biotherapeutics Inc.	Stock news	Crude Oil Gains 2%; GE Vernova Shares Fall After Q2 Earnings	Benzinga	Jul 22, 12:09:13 PM ET
LABTLakewood-Amedex Biotherapeutics Inc.	Press release	Lakewood-Amedex Biotherapeutics Highlights Nu-3 Resistance Data in Response to National Action Plan of Presidential Advisory Council on Combating Antibiotic Resistant Bacteria	PRNewsWire	Jul 22, 8:02:00 AM ET
LABTLakewood-Amedex Biotherapeutics Inc.	Stock news	Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. MBX Biosciences (NASDAQ:MBX) Critical Survey	Defense World	Jul 17, 5:49:10 AM ET
LABTLakewood-Amedex Biotherapeutics Inc.	Press release	Lakewood-Amedex Biotherapeutics Announces Preclinical Safety Data Supporting Clinical Dose Selection for Upcoming Phase 2a Trial of Nu-3 Gel	PRNewsWire	Jul 15, 8:02:00 AM ET
LABTLakewood-Amedex Biotherapeutics Inc.	Press release	Lakewood-Amedex Biotherapeutics Supports Reintroduction of the PASTEUR Act and Focus on Combating Antimicrobial Resistance	PRNewsWire	Jul 7, 8:02:00 AM ET
LABTLakewood-Amedex Biotherapeutics Inc.	Press release	Lakewood-Amedex Biotherapeutics Announces World-Renowned Expert David G. Armstrong, M.D.	PRNewsWire	Jun 25, 8:02:00 AM ET
LABTLakewood-Amedex Biotherapeutics Inc.	Press release	Lakewood-Amedex Biotherapeutics Secures Composition of Matter Patent Protecting New Bisphosphocin® Compounds Being Developed for High-Need Antimicrobial Infections	PRNewsWire	Jun 22, 8:02:00 AM ET
LABTLakewood-Amedex Biotherapeutics Inc.	Press release	Lakewood-Amedex Biotherapeutics to Present at Life Sciences Virtual Investor Forum	PRNewsWire	Jun 16, 8:02:00 AM ET
LABTLakewood-Amedex Biotherapeutics Inc.	Press release	Lakewood-Amedex Biotherapeutics Announces Agreement with PERI to Serve as CRO for Phase 2 Clinical Trial of Nu-3	PRNewsWire	May 12, 8:02:00 AM ET

FAQ

Questions about Lakewood-Amedex Biotherapeutics Inc.

What does Lakewood-Amedex Biotherapeutics Inc. do?

What is LABT's market cap?

Lakewood-Amedex Biotherapeutics Inc. (LABT) is a listed stock with a live quote. The latest market cap on this page is $455,171.

Where is Lakewood-Amedex Biotherapeutics Inc. headquartered?

Lakewood-Amedex Biotherapeutics Inc. is headquartered in University Park, FL.

How do I get LABT news from the API?

Call GET /v1/news?tickers=LABT. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.

How far back does LABT news go?

Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for LABT, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.

Is the LABT price on this page from the API?

The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.

Can I use the Pro plan commercially?

No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 250 REST requests a day, 1 WebSocket connection, 5 requests per second, and 2,500 WebSocket messages a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs